Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Xenon (XENE)
NASDAQ:XENE
Holding XENE?
Track your performance easily
XENE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$27.99 - $50.99
Previous Close$42.92
Volume966.68K
Average Volume (3M)401.87K
Market Cap
$3.24B
Enterprise Value$2.55B
Total Cash (Recent Filing)$699.60M
Total Debt (Recent Filing)$10.43M
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Aug 06, 2024EPS Estimate
-$0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.71
Shares Outstanding75,468,883
10 Day Avg. Volume403,757
30 Day Avg. Volume401,870
Standard Deviation0.18
R-Squared0.13
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)3.19
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-16.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-27.13
Forecast
1Y Price Target
$56.88Price Target Upside35.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Xenon News
PremiumCompany Announcements
Xenon Pharmaceuticals to Present at CNS Virtual Conference
PremiumCompany Announcements
Xenon’s Azetukalner Marks Success in Epilepsy Treatment
Bulls Say, Bears Say
Bulls Say
Clinical Trial AdvancementsPatient enrollment in the phase 3 epilepsy program is progressing, demonstrating advancement in the company's clinical trials.
Financial StabilityThe company ended the year with a robust cash reserve, ensuring a financial runway into 2027 and showcasing strong financial planning.
Stock PerformanceAnalysts maintain a Buy rating with increased price targets, reflecting confidence in potential future revenues and the company's stock performance.
Bears Say
Clinical TrialsThe key trial, X-TOLE2, is now expected to complete enrollment later than the prior timeline.
CompetitionCompetitor's early safety data look promising with a limited immediate impact to XEN1101.
Financial PerformanceXENE reported a Q4 net loss of $44.7MM.
---
Ownership Overview
6.15% Insiders
28.78% Mutual Funds
2.30% Other Institutional Investors
62.77% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
XENE FAQ
What was Xenon’s price range in the past 12 months?
Xenon lowest stock price was $27.98 and its highest was $50.99 in the past 12 months.
What is Xenon’s market cap?
Currently, no data Available
When is Xenon’s upcoming earnings report date?
Xenon’s upcoming earnings report date is Aug 06, 2024 which is 95 days ago.
How were Xenon’s earnings last quarter?
Xenon released its earnings results on May 09, 2024. The company reported -$0.62 earnings per share for the quarter, beating the consensus estimate of -$0.664 by $0.044.
Is Xenon overvalued?
According to Wall Street analysts Xenon’s price is currently Undervalued.
Does Xenon pay dividends?
Xenon does not currently pay dividends.
What is Xenon’s EPS estimate?
Xenon’s EPS estimate is -$0.7.
How many shares outstanding does Xenon have?
Xenon has 75,468,880 shares outstanding.
What happened to Xenon’s price movement after its last earnings report?
Xenon reported an EPS of -$0.62 in its last earnings report, beating expectations of -$0.664. Following the earnings report the stock price went down -4.589%.
Which hedge fund is a major shareholder of Xenon?
Among the largest hedge funds holding Xenon’s share is Driehaus Capital Management LLC. It holds Xenon’s shares valued at 186M.
---
Xenon Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$56.88 (35.75% Upside)
$56.88 (35.75% Upside)
Blogger Sentiment
Bullish
XENE Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 418.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 2.0%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
10.90%
12-Months-Change
Fundamentals
Return on Equity
-23.95%
Trailing 12-Months
Asset Growth
27.67%
Trailing 12-Months
Company Description
Xenon
Xenon Pharmaceuticals, Inc. engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P. Kastelein, and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.
---
XENE Earnings Call
Q1 2024
0:00 / 0:00
---
XENE Stock 12 Month Forecast
Average Price Target
$56.88
▲(35.75% Upside)
Technical Analysis
Best Analysts Covering XENE
1 Year
1 Year Success Rate
12/12 ratings generated profit
1 Year Average Return
+40.67%
reiterated a buy rating 6 months ago
Copying Andrew Tsai's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +40.67% per trade.
---